PMID- 29998375
OWN - NLM
STAT- MEDLINE
DCOM- 20190318
LR  - 20190318
IS  - 1432-0851 (Electronic)
IS  - 0340-7004 (Print)
IS  - 0340-7004 (Linking)
VI  - 67
IP  - 11
DP  - 2018 Nov
TI  - Microenvironmental derived factors modulating dendritic cell function and vaccine 
      efficacy: the effect of prostanoid receptor and nuclear receptor ligands.
PG  - 1789-1796
LID - 10.1007/s00262-018-2205-1 [doi]
AB  - Dendritic cells (DCs) are widely used in DC-based immunotherapies because of 
      their capacity to steer immune responses. So far treatment success is limited and 
      more functional knowledge on how DCs initiate and stably drive specific responses 
      is needed. Many intrinsic and extrinsic factors contribute to how DCs skew the 
      immune response towards immunity or tolerance. The origin and type of DC, its 
      maturation status, but also factors they encounter in the in vitro or in vivo 
      microenvironment they reside in during differentiation and maturation affect this 
      balance. Treatment success of DC vaccines will, therefore, also depend on the 
      presence of these factors during the process of vaccination. Identification and 
      further knowledge of natural and pharmacological compounds that modulate DC 
      differentiation and function towards a specific response may help to improve 
      current DC-based immunotherapies. This review focuses on factors that could 
      improve the efficacy of DC vaccines in (pre-)clinical studies to enhance DC-based 
      immunotherapy, with a particular emphasis on compounds acting on prostanoid or 
      nuclear receptor families.
FAU - Raaijmakers, Tonke K
AU  - Raaijmakers TK
AD  - Radiotherapy and OncoImmunology Laboratory, Department of Radiation Oncology, 
      Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 
      Geert Grooteplein Zuid 32, 6525 GA, Nijmegen, The Netherlands.
AD  - Department of Anesthesiology, Pain and Palliative Medicine, Radboud University 
      Medical Center, Geert Grooteplein 10, 6525 GA, Nijmegen, The Netherlands.
FAU - Ansems, Marleen
AU  - Ansems M
AUID- ORCID: 0000-0003-0196-5755
AD  - Radiotherapy and OncoImmunology Laboratory, Department of Radiation Oncology, 
      Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 
      Geert Grooteplein Zuid 32, 6525 GA, Nijmegen, The Netherlands. 
      marleen.ansems@radboudumc.nl.
LA  - eng
GR  - 016.156.093/Nederlandse Organisatie voor Wetenschappelijk Onderzoek/
GR  - BUIT 2012-5347/KWF Kankerbestrijding/
PT  - Journal Article
PT  - Review
DEP - 20180711
PL  - Germany
TA  - Cancer Immunol Immunother
JT  - Cancer immunology, immunotherapy : CII
JID - 8605732
RN  - 0 (Cancer Vaccines)
RN  - 0 (Ligands)
RN  - 0 (Receptors, Cytoplasmic and Nuclear)
RN  - 0 (Receptors, Prostaglandin)
SB  - IM
MH  - Animals
MH  - Cancer Vaccines/*therapeutic use
MH  - Dendritic Cells/*immunology/metabolism
MH  - Humans
MH  - *Immunotherapy
MH  - Ligands
MH  - Neoplasms/immunology/metabolism/*therapy
MH  - Receptors, Cytoplasmic and Nuclear/*metabolism
MH  - Receptors, Prostaglandin/*metabolism
MH  - Tumor Microenvironment/*immunology
PMC - PMC6208817
OTO - NOTNLM
OT  - Dendritic cells
OT  - Immunotherapy
OT  - Microenvironment
OT  - Nuclear receptors
OT  - Prostanoid receptors
OT  - Vaccine
COIS- The authors declare no conflict of interest.
EDAT- 2018/07/13 06:00
MHDA- 2019/03/19 06:00
PMCR- 2018/07/11
CRDT- 2018/07/13 06:00
PHST- 2018/04/23 00:00 [received]
PHST- 2018/07/09 00:00 [accepted]
PHST- 2018/07/13 06:00 [pubmed]
PHST- 2019/03/19 06:00 [medline]
PHST- 2018/07/13 06:00 [entrez]
PHST- 2018/07/11 00:00 [pmc-release]
AID - 10.1007/s00262-018-2205-1 [pii]
AID - 2205 [pii]
AID - 10.1007/s00262-018-2205-1 [doi]
PST - ppublish
SO  - Cancer Immunol Immunother. 2018 Nov;67(11):1789-1796. doi: 
      10.1007/s00262-018-2205-1. Epub 2018 Jul 11.